Our study took into consideration available literature and personal data regarding uNGAL and plasma/serum NGAL and the impact of routinely used blood parameters (creatinine and ESR) on the progression of CKD and proposed a more clinical, non-limiting interpretation of their impact on CKD progression. This evidence concerns the gene LCN2 and chronic kidney disease.